Author/year/reference

Patients / valves

Success rate

Approach

30-day mortality

Type of study

Eltchaninoff 2011[19]

244 ES68%, CV32%

98.3%

TV 71%
TA 29%

12.7%

Prospective multicenter national registry

Ewe 2011[13]

104 ES100%

92.5%

TV 44%
TA 56%

9.6%                 TV 11.1%         TA 8.5%

Prospective single center with retrospective analysis

Leon 2010 [11]

173/358 ES100%

95.4%

TV 100%

6.4%

Prospective multicenter randomized trial

Bosmans 2011[22]

328 ES43%, CV57%

97%

TV 73%
TA 27%

ES 12%
CV11%

Prospective non-randomized multicenter national registry

Buellesfeld 2011[10]

126 CV100%

83.1%

TV100%

15.2%

Prospective multicenter study

Conradi 2011[9]

28 ES89%, CV11%

96.4%

TV 32.1% TA67.9%

7.1%

Case series: comparative study

Bapat 2011[20]

193 ES100%

100%

TV  44% TA  47.2%   TAo 8.8% 

                         TA 7.7%         TAo 11.8%      

Case series study

Ben-Dor 2011[8]

111

NA

NA

11.7%

Prospective cohort study

Johansson 2011[27]  

40 ES100%

92.5%       TV91%      TA 93%

TV 25%  TA 75%

5%

Case comparative study

Lopez-Otero 2011[12]

186 CV100%

98.8-100%

TV 100%

8.4%

Multicenter study

Bleiziffer 2009[15]

137 ES17% CV83%

98.5%

TV 82%
TA 17%
TAo 1%

12.4%

Single center study

Abdel-Wahab 2011[36]

690/697 ES16% CV84%

98.6%

TV95.5% TA3.7% TAo0.7%

6.7%-15.1%

Multicenter prospective registry

Grube 2011[24]

60 CV100%

96.7%

TV100%

6.7%

Multicenter prospective pilot study

Baan 2010[38]

30 CV100%

90%

TV100%

20%

Single center study

Piazza 2008 [42]

646 CV100%

97%

 

8%

Multicenter registry

Dewey 2008 [21]

21 ES100%

NR

TV TA

9.5%

Single center study

Grube 2007[18]18

86 CV100%

88%

TV100%

12%

Multicenter study

Webb 2007[17]

50 ES100%

86%

TV100%

12%

Single center study

Grube 2006[16]

25 CV100%

84%

TV100%

20%

Single center prospective nonrandomised study


TV=transvascular (transfemoral, transaxillary and subclavian artery); TA= transapical; NA: not available, TAo= transaortic, PCI= percutaneous coronary intervention, ES=
Edwards Sapien bioprosthesis, CV= CoreValve bioprosthesis, NR=not reported
.
Table 2: Current success rate and short-term outcome of transcatheter aortic valve implantation.